New Campaigns from Gilead and ViiV in the Q1 2026 Antiretrovirals (HIV) SnapShot 

Gilead introduced a DTC campaign for Yeztugo, while Biktarvy materials discussed updated tablets and campaign theme messaging. New data and corporate leadership were also highlighted. 

Merck announced the presentation of new data for doravirine/islatravir (Idvynso) at CROI 2026.  

ViiV Healthcare announced final efficacy results from the LATITUDE trial for Cabenuva and introduced a DTC campaign theme.